Screener
Arbutus Biopharma Corporation ABUS Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts receivable | 1,312 | 1,447 |
| License receivable from Genevant | 178,741 | — |
| Prepaid expenses and other current assets | 1,732 | 1,538 |
| Total current assets | 277,011 | 94,456 |
| Property and equipment, net of accumulated depreciation and impairment of $224 (December 31, 2025: $213) | 22 | 32 |
| Other non-current assets | 131 | 130 |
| Total assets | $277,164 | $94,618 |
| Liabilities and stockholders’ equity |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's total current assets?
- Arbutus Biopharma Corporation (ABUS) reported total current assets of $277.01M in Q1 2026.
- How has Arbutus Biopharma Corporation's total current assets changed year-over-year?
- Arbutus Biopharma Corporation's total current assets increased by 137.2% year-over-year, from $116.81M to $277.01M.
- What is the long-term trend for Arbutus Biopharma Corporation's total current assets?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's total current assets has grown at a -5.9% compound annual growth rate (CAGR), from $127.7M to $94.46M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Arbutus Biopharma Corporation's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude